Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 614 participants.
Also called NCT06648304
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 614 participants
- Sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
- Registry
-
NCT06648304
-
- Other papers using this trial's data
- Early and prolonged oral edaravone for neuroprotection in acute ischemic stroke: the ERASE-STROKE randomized controlled phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06648304. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-25 (actual); primary completion 2024-06-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- TTYP01 tablets
- Intervention (Drug)
- Placebo (Simulant TTYP01 Tablets)
- Lead sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
Record details
- Record id
cardio:ct-nct06648304- Content hash
ed15ecff0b4d02b8fad0f4baab88bc4bdb622380971c6c4eee20960b9dbef7bf